A. We are unifying our identity under a single name to better reflect who we are and what we do, and to build stronger trust with our stakeholders.

For over three decades, our clinical trials have been conducted as the Australasian Gastro-Intestinal Trials Group (AGITG). To support this work, we later established the GI Cancer Institute (GICI) as the public and fundraising arm in the early 2000s.

This dual branding has caused confusion, duplicated effort, and made it harder for donors to clearly understand who they are supporting.

By adopting a single, consistent name, we can reduce this confusion, strengthen trust, and present a clearer identity to the public, partners, and researchers alike.

The rebrand is part of our 2025–2030 Strategy, which sets a bold vision for growth and impact. A simpler, more recognisable name – GI Cancer Trials – will help us connect more effectively and amplify our work in GI cancer research.

GI Cancer Trials, or GCT, is a name that speaks directly to our core purpose. It’s clear, memorable, and easy to pronounce. This shift builds on our history while simplifying how we are known and recognised.

A. Nothing. Our commitment to improving outcomes for people with GI cancer remains unchanged. Our research, staff, and web domain are not changing. Our new logo respects the history of our brand, while modernising the iconic mark we all know.

A. For members, the new name will be launched at the Annual Scientific Meeting (ASM) on 24–27 November 2025. From then, you will see our name appear as “GI Cancer Trials (formerly AGITG)” in member and scientific communications for a transition period of up to 12 months.

We will publicly adopt the new name on 3 February 2026 – this is when our website and social platforms will change to GI Cancer Trials. The change is happening in two stages to maximise the ASM as a launch platform with members, while aligning the public launch with existing donor communications scheduled for the new year. It also ensures members are well informed and engaged before the broader public and donor community launch.

A. A staged plan is in place to ensure a smooth and thoughtful transition. Branding updates and communications will be carefully managed to reduce disruption and encourage adoption of the new name.

The new name will be launched at the Annual Scientific Meeting (ASM) on 24–27 November 2025. The rebrand and new strategy was presented to all research committees ahead of the ASM.

From 1 December, all members will be notified of the change with multiple communications over December, January and February to cement the change.

A: Yes – while the name is simplified, our work across Australia and Aotearoa New Zealand remains central. This will be reflected in our branding visuals and communications.

A. The new name reflects input from members during the Strategy Workshop held in March 2025. Every 4–5 years, we hold a workshop with members, committee leaders, board directors and staff to review our organisational strategy and develop a new strategy for the next 4–5 years. At the workshop, our name was a hot topic of conversation. Feedback included that AGITG is a complicated acronym, people get it wrong all the time, it doesn’t contain the word “cancer” which confuses international partners, and having two names seems unnecessarily complex.

Following this workshop and further consultation, the decision was made to unify the organisation’s identity under one name. Our new strategy sets a bold vision for growth and impact, and a simpler, more recognisable name will help us achieve these goals.

We’ll continue to consult and keep members informed as we roll out the changes.

A. No – your membership remains the same. The rebrand is about clearer communication, not changes to member programs.

A. All regulatory and contractual details remain the same. This is a new business name, and we are not changing our legal name at this stage.

A. Trials that are due to close to recruitment within 12 months will remain AGITG-branded trials. A transition plan for trials with a longer recruitment completion period is underway and will be rolled out gradually. All sites we work with will been notified of this change. We’ll provide guidance and support to ensure a smooth transition across trial sites.

A. We advise the use of “GI Cancer Trials (formerly AGITG)” for up to 12 months in research presentations. ‘Australia and Aotearoa New Zealand’ can be added after our name for international presentations and publications. Our research team can assist if you have any questions.

A. No – the rebrand is funded separately and carefully scoped to avoid impacting research budgets.

A. Please contact us at info@gicancer.org.au and we can direct your question to the relevant team.